242 Promising long term outcome of weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC)

Belani, Chandra P.; Aisner, Joseph; R, Day; Ramanathan, R. K.; Jett, J. R.; Capozzoli, M.J.; Bahri, Sanjeev; Hiponia, D.

doi:10.1016/s0169-5002(97)89622-5

Cited by 24 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rationale for using low-dose paclitaxel and carboplatin with radiotherapy was based on clinical studies demonstrating activity of the two drugs in this approach. 13,14 Although concurrent low-dose paclitaxel and carboplatin was added to radiation later during the study, the median OS observed in our study (15.3 months with PC alone and 16.0 months with TPC) is comparable with results reported in several other randomized trials of full-dose chemotherapy administered concurrently with radiation. [3][4][5][6] Thalidomide was also investigated in combination with chemotherapy in three randomized studies in advanced lung cancer in Europe-one in NSCLC and the other two in small-cell lung cancer (SCLC).…”

Section: Discussionsupporting

confidence: 86%

Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study

Hoang

Dahlberg

Schiller

et al. 2012

JCO

View full text Add to dashboard Cite

A B S T R A C T PurposeThe primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide. Patients and MethodsPatients were randomly assigned to the control arm (PC) involving two cycles of induction paclitaxel 225 mg/m 2 and carboplatin area under the curve (AUC) 6 followed by 60 Gy thoracic radiation administered concurrently with weekly paclitaxel 45 mg/m 2 and carboplatin AUC 2, or to the experimental arm (TPC), receiving the same treatment in combination with thalidomide at a starting dose of 200 mg daily. The protocol allowed an increase in thalidomide dose up to 1,000 mg daily based on patient tolerability. ResultsA total of 546 patients were eligible, including 275 in the PC arm and 271 in the TPC arm. Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P ϭ .99), 7.8 months (P ϭ .96), and 38.2% (P ϭ .47), respectively, for patients in the TPC arm. Overall, there was higher incidence of grade 3 toxicities in patients treated with thalidomide. Several grade 3 or higher events were observed more often in the TPC arm, including thromboembolism, fatigue, depressed consciousness, dizziness, sensory neuropathy, tremor, constipation, dyspnea, hypoxia, hypokalemia, rash, and edema. Low-dose aspirin did not reduce the thromboembolic rate. ConclusionThe addition of thalidomide to chemoradiotherapy increased toxicities but did not improve survival in patients with locally advanced NSCLC.

show abstract

Section: Discussionsupporting

confidence: 86%

Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study

Hoang

Dahlberg

Schiller

et al. 2012

JCO

View full text Add to dashboard Cite

show abstract

“…This regimen had rapidly been adopted in clinical practice as one of the most commonly used treatments for unresectable NSCLC following the publication of several prospective studies in the early to mid 1990s that suggested excellent survival and little severe toxicity (51,52). Forty-one patients treated on CALGB 9534 received two cycles of induction paclitaxel and carboplatin chemotherapy followed by 66 Gy radiotherapy with weekly paclitaxel (50 mg/m 2 ) and carboplatin (area under the curve = 2).…”

Section: Gastrointestinal Malignanciesmentioning

confidence: 99%

Radiation Oncology Research in the Cancer and Leukemia Group B

Seagren¹,

Glicksman²

2006

Clinical Cancer Research

View full text Add to dashboard Cite

Radiation oncology initiatives have been an integral component in the evolution of multidisciplinary research in the Cancer and Leukemia Group B. Although early studies in the Group primarily focused on chemotherapy for hematologic and pediatric malignancies, the Radiation Oncology Committee was established in 1972, reflecting the broadening scope of clinical investigation with an increased emphasis on solid tumor research. A major early contribution of the Radiation Oncology Committee was the recognition of the importance of formalized radiation quality review, which led to the development of the Quality Assurance Review Center. The committee has been instrumental in designing trials, in conjunction with our medical oncology and surgical oncology colleagues, to assess multimodality therapy. The results of many of these studies have had important implications for clinical practice. Recent efforts have explored our major research theme of treatment intensification via radiotherapy dose modulation and novel combinations of radiotherapy with sensitizing agents, with an emphasis on safely implementing advanced technologies in the cooperative group setting.

show abstract

“…Newer chemotherapeutic agents, such as paclitaxel, have been successfully integrated with radiotherapy in combined modality programs [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

“…The concurrent approach seems to increase the rate of adverse events, particularly oesophagitis and pneumonitis. Several more recent phase II trials that combined carboplatin, paclitaxel and concurrent radiotherapy have reported improvements in survival, with acceptable rates of adverse effects [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial

et al. 2007

View full text Add to dashboard Cite

242 Promising long term outcome of weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC)

Cited by 24 publications

References 0 publications

Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study

Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study

Radiation Oncology Research in the Cancer and Leukemia Group B

Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial

Contact Info

Product

Resources

About